Loading…
Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.
Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.
Same company as the Shenzhen-listed A shares. Is paid for services rather than for drugs: chemists billed by headcount for discovery work, and per project or batch for development and manufacturing. US and European clients provide most of the revenue.
In one line: A Chinese CRO/CDMO akin to a smaller Charles River Laboratories.
Moat: narrow (process know-how, customer qualification, scale). Deep scientific know-how and long-standing outsourcing relationships across the drug-development chain.
Headquarters: Beijing, China · Founded: 1996 · Employees: 25,088
Size Pharmaron Beijing (3759.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $11.3B, the 154th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$29.14 on 6 Nov 2026.
Performance Over six months the shares gained 44.7%, against +3.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 24.2% over the last twelve months (peer median +13.8%); the operating margin is 14.4% (peer median 17.0%).
Valuation It trades at 22.9× forward earnings against a peer median of 30.9× (8th cheapest of 18).
Capital Return on invested capital runs 1.5 points below its cost of capital (13.9% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$18.2B | HK$15.3B | HK$13.3B | HK$12.7B | HK$11.9B |
| Revenue growth | — | +15% | +5% | +7% | — |
| Gross profit | HK$7.07B | HK$4.98B | HK$4.50B | HK$4.27B | HK$4.14B |
| EBITDA | n/a | HK$3.60B | HK$3.10B | HK$2.94B | HK$2.83B |
| Net income | HK$2.01B | HK$1.80B | HK$1.94B | HK$1.77B | HK$1.60B |
| Free cash flow | -HK$236M | HK$674M | HK$633M | -HK$68.8M | -HK$867M |
| Capital expenditure | HK$3.42B | HK$2.89B | HK$2.21B | HK$3.17B | HK$3.43B |
| Total debt | HK$8.74B | HK$7.84B | HK$6.36B | HK$10.7B | HK$6.89B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pharmaron Beijing 3759.HK | $11.3B | +45% | +24% | 14% | 22.9× | n/a |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| Asymchem Laboratories (Tianjin) 6821.HK | $8.19B | +22% | +24% | 17% | 29.2× | n/a |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3759.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.4% | +4.2% | 4th lowest of 21 |
| 6-month return | +44.7% | +3.8% | 2nd highest of 21 |
| Distance from 52-week high | -16.4% | -10.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +24.2% | +13.8% | 7th highest of 20 |
| Operating margin | 14.4% | 17.0% | 10th lowest of 20 |
| Forward P/E | 22.9× | 30.9× | 8th cheapest of 18 |
| ROIC minus cost of capital | -1.5 pp | +1.6 pp | 6th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharmaron Beijing 3759.HK | Hong Kong | $11.3B | +45% | +24% | 14% | 22.9× | n/a | n/a |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% | +6.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% | +12.5% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 6.6× | -10.3% | +7.4% |